SystImmune to Present New ADC Data at ASCO 2026
SystImmune, a clinical-stage biotechnology company, is set to present new clinical data from its antibody-drug conjugate (ADC) pipeline at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The company will showcase data from four clinical programs, including iza-bren (izalontamab brengitecan), a bispecific ADC developed in collaboration with Bristol Myers Squibb. The presentations will cover late-stage trials of iza-bren in triple-negative breast cancer and esophageal squamous cell carcinoma, as well as early-stage studies of other ADCs targeting different tumor-associated antigens. These programs aim to demonstrate the clinical potential and scalability of SystImmune's platform in treating various difficult-to-treat cancers. 
